Glaukos Corporation (NYSE:GKOS) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Glaukos Corporation (NYSE:GKOS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On September 14, 2017,in connection with its Investor Day meeting being held today in New York City, Glaukos Corporation issued a press release providing an update regarding its pipeline products and revising 2017 net sales guidance. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.


GLAUKOS Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 gkos_Ex99_1 Exhibit 99.1   FOR IMMEDIATE RELEASE   Contact: Sheree Aronson VP,…
To view the full exhibit click here

About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.